Search

Your search keyword '"Cikes, M"' showing total 290 results
Start Over Author "Cikes, M"
290 results on '"Cikes, M"'

1. Lower Platelet Count Following Induction with Antithymocyte Globulin is Associated with a Lower Incidence of Cardiac Allograft Vasculopathy

Author

Skoric, B., primary, Fabijanovic, D., additional, Mjehovic, P., additional, Nekic, A., additional, Jakus, N., additional, Planinc, I., additional, Pasalic, M., additional, Jurin, H., additional, Samardzic, J., additional, Cikes, M., additional, Gasparovic, H., additional, Colak, Z., additional, and Milicic, D., additional

Published
2024
Full Text
View/download PDF

2. Intravenous angiotensin II as an add-on to standard of care vasopressors in patients with refractory shock on mechanical circulatory support: a single centre retrospective case series

Author

Sipus, D, primary, Momcilovic, M, additional, Percin, L, additional, Fabijanovic, D, additional, Pasara, V, additional, Jakus, N, additional, Planinc, I, additional, Pasalic, M, additional, Jurin, H, additional, Samardzic, J, additional, Skoric, B, additional, Cikes, M, additional, Milicic, D, additional, and Lovric, D, additional

Published
2024
Full Text
View/download PDF

3. Predominance of a rare transthyretin mutation (p.Asp38Glu) in patients with hATTR cardiomyopathy: initial data from the Croatian Transthyretin Cardiac Amyloidosis Registry (CroATTR)

Author

Sipus, D, primary, Loncaric, F, additional, Jakus, N, additional, Fabijanovic, D, additional, Samardzic, J, additional, Skoric, B, additional, Mustapic, I, additional, Bakovic Kramaric, D, additional, Vinter, O, additional, Raljevic, D, additional, Ruzic, A, additional, Borovecki, F, additional, Milicic, D, additional, Cikes, M, additional, and Planinc, I, additional

Published
2023
Full Text
View/download PDF

6. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Author

Lyon, A. R., Lopez-Fernandez, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., de Azambuja, E., de Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D., Moslehi, J., Moura, B., Salinger, S. S., Stephens, R., Suter, T. M., Szmit, S., Tamargo, J., Thavendiranathan, P., Tocchetti, C. G., van der Meer, P., van der Pal, H. J. H., Lancellotti, P., Thuny, F., Abdelhamid, M., Aboyans, V., Aleman, B., Alexandre, J., Barac, A., Borger, M. A., Casado-Arroyo, R., Cautela, J., Celutkiene, J., Cikes, M., Cohen-Solal, A., Dhiman, K., Ederhy, S., Edvardsen, T., Fauchier, L., Fradley, M., Grapsa, J., Halvorsen, S., Heuser, M., Humbert, M., Jaarsma, T., Kahan, T., Konradi, A., Koskinas, K. C., Kotecha, D., Ky, B., Landmesser, U., Lewis, B. S., Linhart, A., Lip, G. Y. H., Lochen, M. -L., Malaczynska-Rajpold, K., Metra, M., Mindham, R., Moonen, M., Neilan, T. G., Nielsen, J. C., Petronio, A. -S., Prescott, E., Rakisheva, A., Salem, J. -E., Savarese, G., Sitges, M., Ten Berg, J., Touyz, R. M., Tycinska, A., Wilhelm, M., Zamorano, J. L., Cardiovascular Centre (CVC), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE), Group, ESC Scientific Document, Lyon, Alexander R, López-Fernández, Teresa, Couch, Liam S, Asteggiano, Riccardo, Aznar, Marianne C, Bergler-Klein, Jutta, Boriani, Giuseppe, Cardinale, Daniela, Cordoba, Raul, Cosyns, Bernard, Cutter, David J, de Azambuja, Evandro, de Boer, Rudolf A, Dent, Susan F, Farmakis, Dimitrio, Gevaert, Sofie A, Gorog, Diana A, Herrmann, Joerg, Lenihan, Daniel, Moslehi, Javid, Moura, Brenda, Salinger, Sonja S, Stephens, Richard, Suter, Thomas M, Szmit, Sebastian, Tamargo, Juan, Thavendiranathan, Paaladinesh, Tocchetti, Carlo G, van der Meer, Peter, van der Pal, Helena J H, Cardiology, Clinical sciences, and Cardio-vascular diseases

Subjects
Cardiac magnetic resonance, Cancer survivors, Vascular endothelial growth factor inhibitors (VEGFi), Myocarditi, Guideline, Anthracycline, Arrhythmias, Medical Oncology, T-CELL THERAPY, Coronary artery disease, Strain, RECURRENT VENOUS THROMBOEMBOLISM, Amyloid light-chain cardiac amyloidosis, Androgen deprivation therapy, Atrial fibrillation, Biomarkers, Cancer, Carcinoid syndrome, Cardiac tumour, Cardio-oncology, Cardiotoxicity, Chemotherapy, Echocardiography, Fluoropyrimidine, Guidelines, Haematopoietic stem cell transplantation, Heart failure, Hormone therapy, Hypertension, Immunotherapy, Ischaemic heart disease, Myocarditis, Pericardial disease, Proteasome inhibitors, Pulmonary hypertension, QTc prolongation, Radiotherapy, Risk stratification, Thrombosis, Trastuzumab, Valvular heart disease, Venous thromboembolism, Neoplasms, Proteasome inhibitor, Amyloid light-chain cardiac amyloidosi, IMMUNE CHECKPOINT INHIBITORS, Cardiotoxicity/diagnostic imaging, Heart, General Medicine, Hematology, MOLECULAR-WEIGHT HEPARIN, BRAIN NATRIURETIC PEPTIDE, oncology, Cancer survivor, Thrombosi, CORONARY-ARTERY-DISEASE, Cardiology and Cardiovascular Medicine, TYROSINE KINASE INHIBITOR, Arrhythmia, Neoplasms/diagnostic imaging, Antineoplastic Agents, Humans, Radiology, Nuclear Medicine and imaging, EARLY BREAST-CANCER, CARCINOID HEART-DISEASE, Antineoplastic Agents/therapeutic use, Biomarker, AORTIC-VALVE-REPLACEMENT, Radiation Oncology
Published
2022
Full Text
View/download PDF

7. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial

Author

Cikes, M, Planinc, I, Claggett, B, Cunningham, J, Milicic, D, Sweitzer, N, Senni, M, Gori, M, Linssen, G, Shah, S, Packer, M, Pfeffer, M, Zile, M, Anand, I, Chiang, L, Lam, C, Redfield, M, Desai, A, Mcmurray, J, Solomon, S, Cikes M., Planinc I., Claggett B., Cunningham J., Milicic D., Sweitzer N., Senni M., Gori M., Linssen G., Shah S. J., Packer M., Pfeffer M., Zile M. R., Anand I., Chiang L. -M., Lam C. S. P., Redfield M., Desai A. S., McMurray J. J. V., Solomon S. D., Cikes, M, Planinc, I, Claggett, B, Cunningham, J, Milicic, D, Sweitzer, N, Senni, M, Gori, M, Linssen, G, Shah, S, Packer, M, Pfeffer, M, Zile, M, Anand, I, Chiang, L, Lam, C, Redfield, M, Desai, A, Mcmurray, J, Solomon, S, Cikes M., Planinc I., Claggett B., Cunningham J., Milicic D., Sweitzer N., Senni M., Gori M., Linssen G., Shah S. J., Packer M., Pfeffer M., Zile M. R., Anand I., Chiang L. -M., Lam C. S. P., Redfield M., Desai A. S., McMurray J. J. V., and Solomon S. D.

Abstract

Objectives: In this study, the authors sought to assess the relationship between AFF and outcomes, the treatment response to sacubitril/valsartan and first-detected AFF in patients with HFpEF enrolled in the PARAGON-HF trial. Background: Atrial fibrillation and flutter (AFF) are common in heart failure with preserved ejection fraction (HFpEF) and increase the risk of adverse outcomes. Methods: A total of 4,776 patients formed 3 groups: those with AFF according to electrocardiography (ECG) at enrollment (n = 1,552; 33%), those with history of AFF but without AFF on ECG at enrollment (n = 1,005; 21%), and those without history of AFF or AFF on ECG at enrollment (n = 2,219, 46%). We assessed outcomes, treatment response to sacubitril/valsartan in each group, and the risk associated with first-detected AFF in patients without any known AFF. The primary outcome was a composite of total heart failure hospitalizations and cardiovascular death. Results: History of AFF and AFF at enrollment were associated with higher risk of the primary outcome (risk ratio [RR]: 1.36 [95% CI: 1.12-1.65] and RR: 1.31 [1.11-1.54], respectively), than no AFF. Neither history of AFF nor AFF at enrollment modified the treatment effect of sacubitril/valsartan. Post randomization AFF occurred in 12% of patients without previous AFF and was associated with 2.8-fold higher risk of the primary outcome, but it was not influenced by sacubitril/valsartan. Conclusions: History of AFF and AFF on ECG at enrollment were associated with a higher risk of the primary outcome. First-detected AFF was not influenced by sacubitril/valsartan, yet it was associated with increased risk of all subsequent outcomes and may represent a potential target for future HFpEF trials. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711)

Published
2022

8. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial

Author

Pfeffer, M, Claggett, B, Lewis, E, Granger, C, Kober, L, Maggioni, A, Mann, D, Mcmurray, J, Rouleau, J, Solomon, S, Steg, P, Berwanger, O, Cikes, M, De Pasquale, C, Fernandez, A, Filippatos, G, Jering, K, Landmesser, U, Menon, V, Merkely, B, Petrie, M, Petrov, I, Schou, M, Senni, M, Sim, D, van der Meer, P, Lefkowitz, M, Zhou, Y, Wang, Y, Braunwald, E, Pfeffer M. A., Claggett B., Lewis E. F., Granger C. B., Kober L., Maggioni A. P., Mann D. L., McMurray J. J. V., Rouleau J. -L., Solomon S. D., Steg P. G., Berwanger O., Cikes M., De Pasquale C. G., Fernandez A., Filippatos G., Jering K., Landmesser U., Menon V., Merkely B., Petrie M. C., Petrov I., Schou M., Senni M., Sim D., van der Meer P., Lefkowitz M., Zhou Y., Wang Y., Braunwald E., Pfeffer, M, Claggett, B, Lewis, E, Granger, C, Kober, L, Maggioni, A, Mann, D, Mcmurray, J, Rouleau, J, Solomon, S, Steg, P, Berwanger, O, Cikes, M, De Pasquale, C, Fernandez, A, Filippatos, G, Jering, K, Landmesser, U, Menon, V, Merkely, B, Petrie, M, Petrov, I, Schou, M, Senni, M, Sim, D, van der Meer, P, Lefkowitz, M, Zhou, Y, Wang, Y, Braunwald, E, Pfeffer M. A., Claggett B., Lewis E. F., Granger C. B., Kober L., Maggioni A. P., Mann D. L., McMurray J. J. V., Rouleau J. -L., Solomon S. D., Steg P. G., Berwanger O., Cikes M., De Pasquale C. G., Fernandez A., Filippatos G., Jering K., Landmesser U., Menon V., Merkely B., Petrie M. C., Petrov I., Schou M., Senni M., Sim D., van der Meer P., Lefkowitz M., Zhou Y., Wang Y., and Braunwald E.

Published
2022

9. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

Author

Zeppenfeld, K., Tfelt-Hansen, J., Riva, M. de, Winkel, B.G., Behr, E.R., Blom, N.A., Charron, P., Corrado, D., Dagres, N., Chillou, C. de, Eckardt, L., Friede, T., Haugaa, K.H., Hocini, M., Lambiase, P.D., Marijon, E., Merino, J.L., Peichl, P., Priori, S.G., Reichlin, T., Schulz-Menger, J., Sticherling, C., Tzeis, S., Verstrael, A., Volterrani, M., Cikes, M., Kirchhof, P., Abdelhamid, M., Aboyans, V., Arbelo, E., Arribas, F., Asteggiano, R., Basso, C., Bauer, A., Bertaglia, E., Biering-Sorensen, T., Blomstrom-Lundqvist, C., Borger, M.A., Celutkiene, J., Cosyns, B., Falk, V., Fauchier, L., Gorenek, B., Halvorsen, S., Hatala, R., Heidbuchel, H., Kaab, S., Konradi, A., Koskinas, K.C., Kotecha, D., Landmesser, U., Lewis, B.S., Linhart, A., Lochen, M.L., Lund, L.H., Metzner, A., Mindham, R., Nielsen, J.C., Norekval, T.M., Patten, M., Prescott, E., Rakisheva, A., Remme, C.A., Roca-Luque, I., Sarkozy, A., Scherr, D., Sitges, M., Touyz, R.M., Mieghem, N. van, Velagic, V., Viskin, S., Volders, P.G.A., Task Force Members, and ESC Scientific Document Group

Subjects
Genetic testing, Cardiac magnetic resonance, Sudden death, Ventricular tachycardia, Primary electrical disease, Guidelines, Recommendations, Chronic coronary artery disease, Risk calculator, Sudden cardiac death, Implantable cardioverter defibrillator, Ventricular arrhythmia, Catheter ablation, Anti-arrhythmic drugs, Ventricular fibrillation, Cardiomyopathies, Risk stratification, Premature ventricular complex
Published
2022

10. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial

Author

Cikes M., Planinc I., Claggett B., Cunningham J., Milicic D., Sweitzer N., Senni M., Gori M., Linssen G., Shah S. J., Packer M., Pfeffer M., Zile M. R., Anand I., Chiang L. -M., Lam C. S. P., Redfield M., Desai A. S., McMurray J. J. V., Solomon S. D., Cikes, M, Planinc, I, Claggett, B, Cunningham, J, Milicic, D, Sweitzer, N, Senni, M, Gori, M, Linssen, G, Shah, S, Packer, M, Pfeffer, M, Zile, M, Anand, I, Chiang, L, Lam, C, Redfield, M, Desai, A, Mcmurray, J, and Solomon, S

Subjects
heart failure with preserved ejection fraction, heart failure outcome, sacubitril/valsartan, echocardiography, atrial fibrillation
Abstract

Objectives: In this study, the authors sought to assess the relationship between AFF and outcomes, the treatment response to sacubitril/valsartan and first-detected AFF in patients with HFpEF enrolled in the PARAGON-HF trial. Background: Atrial fibrillation and flutter (AFF) are common in heart failure with preserved ejection fraction (HFpEF) and increase the risk of adverse outcomes. Methods: A total of 4,776 patients formed 3 groups: those with AFF according to electrocardiography (ECG) at enrollment (n = 1,552; 33%), those with history of AFF but without AFF on ECG at enrollment (n = 1,005; 21%), and those without history of AFF or AFF on ECG at enrollment (n = 2,219, 46%). We assessed outcomes, treatment response to sacubitril/valsartan in each group, and the risk associated with first-detected AFF in patients without any known AFF. The primary outcome was a composite of total heart failure hospitalizations and cardiovascular death. Results: History of AFF and AFF at enrollment were associated with higher risk of the primary outcome (risk ratio [RR]: 1.36 [95% CI: 1.12-1.65] and RR: 1.31 [1.11-1.54], respectively), than no AFF. Neither history of AFF nor AFF at enrollment modified the treatment effect of sacubitril/valsartan. Post randomization AFF occurred in 12% of patients without previous AFF and was associated with 2.8-fold higher risk of the primary outcome, but it was not influenced by sacubitril/valsartan. Conclusions: History of AFF and AFF on ECG at enrollment were associated with a higher risk of the primary outcome. First-detected AFF was not influenced by sacubitril/valsartan, yet it was associated with increased risk of all subsequent outcomes and may represent a potential target for future HFpEF trials. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711)

Published
2022

11. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

Author

Visseren, F, Mach, F, Smulders, Y, Carballo, D, Koskinas, K, Back, M, Benetos, A, Biffi, A, Boavida, J, Capodanno, D, Cosyns, B, Crawford, C, Davos, C, Desormais, I, Di Angelantonio, E, Duran, O, Halvorsen, S, Richard Hobbs, F, Hollander, M, Jankowska, E, Michal, M, Sacco, S, Sattar, N, Tokgozoglu, L, Tonstad, S, Tsioufis, K, van Dis, I, van Gelder, I, Wanner, C, Williams, B, De Backer, G, Regitz-Zagrosek, V, Aamodt, A, Abdelhamid, M, Aboyans, V, Albus, C, Asteggiano, R, Borger, M, Brotons, C, Celutkiene, J, Cifkova, R, Cikes, M, Cosentino, F, Dagres, N, De Backer, T, De Bacquer, D, Delgado, V, Ruijter, H, Dendale, P, Drexel, H, Falk, V, Fauchier, L, Ference, B, Ferrieres, J, Ferrini, M, Fisher, M, Fliser, D, Fras, Z, Gaita, D, Giampaoli, S, Gielen, S, Graham, I, Jennings, C, Jorgensen, T, Kautzky-Willer, A, Kavousi, M, Koenig, W, Konradi, A, Kotecha, D, Landmesser, U, Lettino, M, Lewis, B, Linhart, A, Lochen, M, Makrilakis, K, Mancia, G, Marques-Vidal, P, Mcevoy, J, Mcgreavy, P, Merkely, B, Neubeck, L, Nielsen, J, Perk, J, Petersen, S, Petronio, A, Piepoli, M, Pogosova, N, Prescott, E, Ray, K, Reiner, Z, Richter, D, Ryden, L, Shlyakhto, E, Sitges, M, Sousa-Uva, M, Sudano, I, Tiberi, M, Touyz, R, Ungar, A, Monique Verschuren, W, Wiklund, O, Wood, D, Zamorano, J, Visseren F., Mach F., Smulders Y. M., Carballo D., Koskinas K. C., Back M., Benetos A., Biffi A., Boavida J. -M., Capodanno D., Cosyns B., Crawford C. A., Davos C. H., Desormais I., Di Angelantonio E., Duran O. H. F., Halvorsen S., Richard Hobbs F. D., Hollander M., Jankowska E. A., Michal M., Sacco S., Sattar N., Tokgozoglu L., Tonstad S., Tsioufis K. P., van Dis I., van Gelder I. C., Wanner C., Williams B., De Backer G., Regitz-Zagrosek V., Aamodt A. H., Abdelhamid M., Aboyans V., Albus C., Asteggiano R., Borger M. A., Brotons C., Celutkiene J., Cifkova R., Cikes M., Cosentino F., Dagres N., De Backer T., De Bacquer D., Delgado V., Ruijter H. D., Dendale P., Drexel H., Falk V., Fauchier L., Ference B. A., Ferrieres J., Ferrini M., Fisher M., Fliser D., Fras Z., Gaita D., Giampaoli S., Gielen S., Graham I., Jennings C., Jorgensen T., Kautzky-Willer A., Kavousi M., Koenig W., Konradi A., Kotecha D., Landmesser U., Lettino M., Lewis B. S., Linhart A., Lochen M. -L., Makrilakis K., Mancia G., Marques-Vidal P., McEvoy J. W., McGreavy P., Merkely B., Neubeck L., Nielsen J. C., Perk J., Petersen S. E., Petronio A. S., Piepoli M., Pogosova N. G., Prescott E. I. B., Ray K. K., Reiner Z., Richter D. J., Ryden L., Shlyakhto E., Sitges M., Sousa-Uva M., Sudano I., Tiberi M., Touyz R. M., Ungar A., Monique Verschuren W. M., Wiklund O., Wood D., Zamorano J. L., Visseren, F, Mach, F, Smulders, Y, Carballo, D, Koskinas, K, Back, M, Benetos, A, Biffi, A, Boavida, J, Capodanno, D, Cosyns, B, Crawford, C, Davos, C, Desormais, I, Di Angelantonio, E, Duran, O, Halvorsen, S, Richard Hobbs, F, Hollander, M, Jankowska, E, Michal, M, Sacco, S, Sattar, N, Tokgozoglu, L, Tonstad, S, Tsioufis, K, van Dis, I, van Gelder, I, Wanner, C, Williams, B, De Backer, G, Regitz-Zagrosek, V, Aamodt, A, Abdelhamid, M, Aboyans, V, Albus, C, Asteggiano, R, Borger, M, Brotons, C, Celutkiene, J, Cifkova, R, Cikes, M, Cosentino, F, Dagres, N, De Backer, T, De Bacquer, D, Delgado, V, Ruijter, H, Dendale, P, Drexel, H, Falk, V, Fauchier, L, Ference, B, Ferrieres, J, Ferrini, M, Fisher, M, Fliser, D, Fras, Z, Gaita, D, Giampaoli, S, Gielen, S, Graham, I, Jennings, C, Jorgensen, T, Kautzky-Willer, A, Kavousi, M, Koenig, W, Konradi, A, Kotecha, D, Landmesser, U, Lettino, M, Lewis, B, Linhart, A, Lochen, M, Makrilakis, K, Mancia, G, Marques-Vidal, P, Mcevoy, J, Mcgreavy, P, Merkely, B, Neubeck, L, Nielsen, J, Perk, J, Petersen, S, Petronio, A, Piepoli, M, Pogosova, N, Prescott, E, Ray, K, Reiner, Z, Richter, D, Ryden, L, Shlyakhto, E, Sitges, M, Sousa-Uva, M, Sudano, I, Tiberi, M, Touyz, R, Ungar, A, Monique Verschuren, W, Wiklund, O, Wood, D, Zamorano, J, Visseren F., Mach F., Smulders Y. M., Carballo D., Koskinas K. C., Back M., Benetos A., Biffi A., Boavida J. -M., Capodanno D., Cosyns B., Crawford C. A., Davos C. H., Desormais I., Di Angelantonio E., Duran O. H. F., Halvorsen S., Richard Hobbs F. D., Hollander M., Jankowska E. A., Michal M., Sacco S., Sattar N., Tokgozoglu L., Tonstad S., Tsioufis K. P., van Dis I., van Gelder I. C., Wanner C., Williams B., De Backer G., Regitz-Zagrosek V., Aamodt A. H., Abdelhamid M., Aboyans V., Albus C., Asteggiano R., Borger M. A., Brotons C., Celutkiene J., Cifkova R., Cikes M., Cosentino F., Dagres N., De Backer T., De Bacquer D., Delgado V., Ruijter H. D., Dendale P., Drexel H., Falk V., Fauchier L., Ference B. A., Ferrieres J., Ferrini M., Fisher M., Fliser D., Fras Z., Gaita D., Giampaoli S., Gielen S., Graham I., Jennings C., Jorgensen T., Kautzky-Willer A., Kavousi M., Koenig W., Konradi A., Kotecha D., Landmesser U., Lettino M., Lewis B. S., Linhart A., Lochen M. -L., Makrilakis K., Mancia G., Marques-Vidal P., McEvoy J. W., McGreavy P., Merkely B., Neubeck L., Nielsen J. C., Perk J., Petersen S. E., Petronio A. S., Piepoli M., Pogosova N. G., Prescott E. I. B., Ray K. K., Reiner Z., Richter D. J., Ryden L., Shlyakhto E., Sitges M., Sousa-Uva M., Sudano I., Tiberi M., Touyz R. M., Ungar A., Monique Verschuren W. M., Wiklund O., Wood D., and Zamorano J. L.

Published
2021

12. Angiotensin receptor–neprilysin inhibition in acute myocardial infarction

Author

Pfeffer, M, Claggett, B, Lewis, E, Granger, C, Kober, L, Maggioni, A, Mann, D, Mcmurray, J, Rouleau, J, Solomon, S, Steg, P, Berwanger, O, Cikes, M, De Pasquale, C, East, C, Fernandez, A, Jering, K, Landmesser, U, Mehran, R, Merkely, B, Mody, F, Petrie, M, Petrov, I, Schou, M, Senni, M, Sim, D, van der Meer, P, Lefkowitz, M, Zhou, Y, Gong, J, Braunwald, E, Pfeffer M. A., Claggett B., Lewis E. F., Granger C. B., Kober L., Maggioni A. P., Mann D. L., McMurray J. J. V., Rouleau J. -L., Solomon S. D., Steg P. G., Berwanger O., Cikes M., De Pasquale C. G., East C., Fernandez A., Jering K., Landmesser U., Mehran R., Merkely B., Mody F. V., Petrie M. C., Petrov I., Schou M., Senni M., Sim D., van der Meer P., Lefkowitz M., Zhou Y., Gong J., Braunwald E., Pfeffer, M, Claggett, B, Lewis, E, Granger, C, Kober, L, Maggioni, A, Mann, D, Mcmurray, J, Rouleau, J, Solomon, S, Steg, P, Berwanger, O, Cikes, M, De Pasquale, C, East, C, Fernandez, A, Jering, K, Landmesser, U, Mehran, R, Merkely, B, Mody, F, Petrie, M, Petrov, I, Schou, M, Senni, M, Sim, D, van der Meer, P, Lefkowitz, M, Zhou, Y, Gong, J, Braunwald, E, Pfeffer M. A., Claggett B., Lewis E. F., Granger C. B., Kober L., Maggioni A. P., Mann D. L., McMurray J. J. V., Rouleau J. -L., Solomon S. D., Steg P. G., Berwanger O., Cikes M., De Pasquale C. G., East C., Fernandez A., Jering K., Landmesser U., Mehran R., Merkely B., Mody F. V., Petrie M. C., Petrov I., Schou M., Senni M., Sim D., van der Meer P., Lefkowitz M., Zhou Y., Gong J., and Braunwald E.

Abstract

BACKGROUND In patients with symptomatic heart failure, sacubitril–valsartan has been found to reduce the risk of hospitalization and death from cardiovascular causes more effectively than an angiotensin-converting–enzyme inhibitor. Trials comparing the effects of these drugs in patients with acute myocardial infarction have been lacking. METHODS We randomly assigned patients with myocardial infarction complicated by a reduced left ventricular ejection fraction, pulmonary congestion, or both to receive either sacubitril–valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily) or ramipril (5 mg twice daily) in addition to recommended therapy. The primary outcome was death from cardiovascular causes or incident heart failure (outpatient symptomatic heart failure or heart failure leading to hospitalization), whichever occurred first. RESULTS A total of 5661 patients underwent randomization; 2830 were assigned to receive sacubitril–valsartan and 2831 to receive ramipril. Over a median of 22 months, a primary-outcome event occurred in 338 patients (11.9%) in the sacubitril–valsartan group and in 373 patients (13.2%) in the ramipril group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P=0.17). Death from cardiovascular causes or hospitalization for heart failure occurred in 308 patients (10.9%) in the sacubitril–valsartan group and in 335 patients (11.8%) in the ramipril group (hazard ratio, 0.91; 95% CI, 0.78 to 1.07); death from cardiovascular causes in 168 (5.9%) and 191 (6.7%), respectively (hazard ratio, 0.87; 95% CI, 0.71 to 1.08); and death from any cause in 213 (7.5%) and 242 (8.5%), respectively (hazard ratio, 0.88; 95% CI, 0.73 to 1.05). Treatment was discontinued because of an adverse event in 357 patients (12.6%) in the sacubitril–valsartan group and 379 patients (13.4%) in the ramipril group. CONCLUSIONS Sacubitril–valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident hear

Published
2021

13. Atrial fibrillation in patients with high-risk acute myocardial infarction – the PARADISE-MI trial

Author

Cikes, M, primary, Jering, K, additional, Claggett, B, additional, Amir, O, additional, Cadena Bonfanti, A J, additional, Cho, M C, additional, Granger, C, additional, Gullestad, L M, additional, Kao, H L, additional, Morais, J, additional, Tanguay, J F, additional, Tokmakova, M, additional, Widimsky, P, additional, and Solomon, S D, additional

Published
2022
Full Text
View/download PDF

14. Trajectory of pulmonary congestion by lung ultrasound in patients with acute myocardial infarction and association with cardiac structure and function

Author

Platz, E, primary, Claggett, B, additional, Jering, K S, additional, Kovacs, A, additional, Cikes, M, additional, Winzer, E B, additional, Rad, A, additional, Lefkowitz, M, additional, Gong, J, additional, Kober, L, additional, McMurray, J J V, additional, Solomon, S D, additional, and Shah, A, additional

Published
2022
Full Text
View/download PDF

15. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

Author

Visseren, F, Mach, F, Smulders, Y, Carballo, D, Koskinas, K, Bäck, M, Benetos, A, Biffi, A, Boavida, J, Capodanno, D, Cosyns, B, Crawford, C, Davos, C, Desormais, I, Di Angelantonio, E, Franco, O, Halvorsen, S, Hobbs, F, Hollander, M, Jankowska, E, Michal, M, Sacco, S, Sattar, N, Tokgozoglu, L, Tonstad, S, Tsioufis, K, van Dis, I, van Gelder, I, Wanner, C, Williams, B, De Backer, G, Regitz-Zagrosek, V, Aamodt, A, Abdelhamid, M, Aboyans, V, Albus, C, Asteggiano, R, Borger, M, Brotons, C, Celutkiene, J, Cifkova, R, Cikes, M, Cosentino, F, Dagres, N, De Backer, T, De Bacquer, D, Delgado, V, Den Ruijter, H, Dendale, P, Drexel, H, Falk, V, Fauchier, L, Ference, B, Ferrières, J, Ferrini, M, Fisher, M, Fliser, D, Fras, Z, Gaita, D, Giampaoli, S, Gielen, S, Graham, I, Jennings, C, Jorgensen, T, Kautzky-Willer, A, Kavousi, M, Koenig, W, Konradi, A, Kotecha, D, Landmesser, U, Lettino, M, Lewis, B, Linhart, A, Lochen, M, Makrilakis, K, Mancia, G, Marques-Vidal, P, Mcevoy, J, Mcgreavy, P, Merkely, B, Neubeck, L, Nielsen, J, Perk, J, Petersen, S, Petronio, A, Piepoli, M, Pogosova, N, Prescott, E, Ray, K, Reiner, Z, Richter, D, Rydén, L, Shlyakhto, E, Sitges, M, Sousa-Uva, M, Sudano, I, Tiberi, M, Touyz, R, Ungar, A, Verschuren, W, Wiklund, O, Wood, D, Zamorano, J, Visseren, FLJ, Smulders, YM, Koskinas, KC, Boavida, JM, Davos, CH, Franco, OH, Hobbs, FDR, Jankowska, EA, Tsioufis, KP, van Gelder, IC, Aamodt, AH, Borger, MA, Ference, BA, Lewis, BS, Lochen, ML, McEvoy, JW, McGreavy, P, Nielsen, JC, Petersen, SE, Petronio, AS, Pogosova, NG, Prescott, EIB, Ray, KK, Richter, DJ, Touyz, RM, Verschuren, WMM, Zamorano, JL, Visseren, F, Mach, F, Smulders, Y, Carballo, D, Koskinas, K, Bäck, M, Benetos, A, Biffi, A, Boavida, J, Capodanno, D, Cosyns, B, Crawford, C, Davos, C, Desormais, I, Di Angelantonio, E, Franco, O, Halvorsen, S, Hobbs, F, Hollander, M, Jankowska, E, Michal, M, Sacco, S, Sattar, N, Tokgozoglu, L, Tonstad, S, Tsioufis, K, van Dis, I, van Gelder, I, Wanner, C, Williams, B, De Backer, G, Regitz-Zagrosek, V, Aamodt, A, Abdelhamid, M, Aboyans, V, Albus, C, Asteggiano, R, Borger, M, Brotons, C, Celutkiene, J, Cifkova, R, Cikes, M, Cosentino, F, Dagres, N, De Backer, T, De Bacquer, D, Delgado, V, Den Ruijter, H, Dendale, P, Drexel, H, Falk, V, Fauchier, L, Ference, B, Ferrières, J, Ferrini, M, Fisher, M, Fliser, D, Fras, Z, Gaita, D, Giampaoli, S, Gielen, S, Graham, I, Jennings, C, Jorgensen, T, Kautzky-Willer, A, Kavousi, M, Koenig, W, Konradi, A, Kotecha, D, Landmesser, U, Lettino, M, Lewis, B, Linhart, A, Lochen, M, Makrilakis, K, Mancia, G, Marques-Vidal, P, Mcevoy, J, Mcgreavy, P, Merkely, B, Neubeck, L, Nielsen, J, Perk, J, Petersen, S, Petronio, A, Piepoli, M, Pogosova, N, Prescott, E, Ray, K, Reiner, Z, Richter, D, Rydén, L, Shlyakhto, E, Sitges, M, Sousa-Uva, M, Sudano, I, Tiberi, M, Touyz, R, Ungar, A, Verschuren, W, Wiklund, O, Wood, D, Zamorano, J, Visseren, FLJ, Smulders, YM, Koskinas, KC, Boavida, JM, Davos, CH, Franco, OH, Hobbs, FDR, Jankowska, EA, Tsioufis, KP, van Gelder, IC, Aamodt, AH, Borger, MA, Ference, BA, Lewis, BS, Lochen, ML, McEvoy, JW, McGreavy, P, Nielsen, JC, Petersen, SE, Petronio, AS, Pogosova, NG, Prescott, EIB, Ray, KK, Richter, DJ, Touyz, RM, Verschuren, WMM, and Zamorano, JL

Published
2022

16. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

Author

Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Back, M., Benetos, A., Biffi, A., Boavida, J. -M., Capodanno, D., Cosyns, B., Crawford, C., Davos, C. H., Desormais, I., DI Angelantonio, E., Franco, O. H., Halvorsen, S., Hobbs, F. D. R., Hollander, M., Jankowska, E. A., Michal, M., Sacco, S., Sattar, N., Tokgozoglu, L., Tonstad, S., Tsioufis, K. P., Van DIs, I., Van Gelder, I. C., Wanner, C., Williams, B., De Backer, G., Regitz-Zagrosek, V., Aamodt, A. H., Abdelhamid, M., Aboyans, V., Albus, C., Asteggiano, R., Borger, M. A., Brotons, C., Ielutkiene, J., Cifkova, R., Cikes, M., Cosentino, F., Dagres, N., De Backer, T., De Bacquer, D., Delgado, V., Den Ruijter, H., Dendale, P., Drexel, H., Falk, V., Fauchier, L., Ference, B. A., Ferrieres, J., Ferrini, M., Fisher, M., Fliser, D., Fras, Z., Gaita, D., Giampaoli, S., Gielen, S., Graham, I., Jennings, C., Jorgensen, T., Kautzky-Willer, A., Kavousi, M., Koenig, W., Konradi, A., Kotecha, D., Landmesser, U., Lettino, M., Lewis, B. S., Linhart, A., Lochen, M. -L., Makrilakis, K., Mancia, G., Marques-Vidal, P., Mcevoy, J. W., Mcgreavy, P., Merkely, B., Neubeck, L., Nielsen, J. C., Perk, J., Petersen, S. E., Petronio, A. S., Piepoli, M., Pogosova, N. G., Prescott, E. I. B., Ray, K. K., Reiner, Z., Richter, D. J., Ryden, L., Shlyakhto, E., Sitges, M., Sousa-Uva, M., Sudano, I., Tiberi, M., Touyz, R. M., Ungar, A., Verschuren, W. M. M., Wiklund, O., Wood, D., Zamorano, J. L., Crawford, C. A., Franco Duran, O. H., Richard Hobbs, F. D., Dis, I. V., Group, ESC Scientific Document, Clinical sciences, Cardio-vascular diseases, and Cardiology

Subjects
medicine.medical_specialty, Epidemiology, Population, air pollution, population, Guidelines, blood pressure, climate change, diabetes, healthy lifestyle, lifetime benefit, lifetime risk, lipids, nutrition, personalized, prevention, psychosocial factors, risk estimation, risk management, shared decision-making, smoking, stepwise approach, Risk Assessment, Humans, Primary Prevention, Risk Factors, Cardiovascular Diseases, Diabetes mellitus, medicine, Intensive care medicine, education, 610 Medicine & health, Risk management, education.field_of_study, business.industry, medicine.disease, Clinical Practice, Blood pressure, guidelines, Heart failure, Lifetime risk, Disease prevention, Cardiology and Cardiovascular Medicine, business, Stepwise approach, 360 Social problems & social services
Abstract

These are the clinical practice guidelines from the European Society of Cardiology on cardiovascular disease prevention in clinical practice, from 2021.

Published
2022
Full Text
View/download PDF

17. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy

Author

Glikson, M., Nielsen, J. C., Kronborg, M. B., Michowitz, Y., Auricchio, A., Barbash, I. M., Barrabes, J. A., Boriani, G., Braunschweig, F., Brignole, M., Burri, H., Coats, A. J. S., Deharo, J. -C., Delgado, V., Diller, G. -P., Israel, C. W., Keren, A., Knops, R. E., Kotecha, D., Leclercq, C., Merkely, B., Starck, C., Thylen, I., Tolosana, J. M., Leyva, F., Linde, C., Abdelhamid, M., Aboyans, V., Arbelo, E., Asteggiano, R., Baron-Esquivias, G., Bauersachs, J., Biffi, M., Birgersdotter-Green, U., Bongiorni, M. G., Borger, M. A., Celutkiene, J., Cikes, M., Daubert, J. -C., Drossart, I., Ellenbogen, K., Elliott, P. M., Fabritz, L., Falk, V., Fauchier, L., Fernandez-Aviles, F., Foldager, D., Gadler, F., De Vinuesa, P. G. G., Gorenek, B., Guerra, J. M., Hermann Haugaa, K., Hendriks, J., Kahan, T., Katus, H. A., Konradi, A., Koskinas, K. C., Law, H., Lewis, B. S., Linker, N. J., Lochen, M. -L., Lumens, J., Mascherbauer, J., Mullens, W., Nagy, K. V., Prescott, E., Raatikainen, P., Rakisheva, A., Reichlin, T., Ricci, R. P., Shlyakhto, E., Sitges, M., Sousa-Uva, M., Sutton, R., Suwalski, P., Svendsen, J. H., Touyz, R. M., Van Gelder, I. C., Vernooy, K., Waltenberger, J., Whinnett, Z., Witte, K. K., Qoriany, A., Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), and Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)

Subjects
Pacemaker, Artificial, Cardiac pacing, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], cardiac resynchronization therapy, heart failure, temporary pacing, law.invention, law, atrial fibrillation, 610 Medicine & health, ComputingMilieux_MISCELLANEOUS, biology, Cardiac Pacing, Artificial, Syncope (genus), Atrial fibrillation, syncope, Cardiology, cardiovascular system, medicine.symptom, guidelines, cardiac pacing, pacemaker, conduction system pacing, pacing indications, alternate site pacing, complications, pacing in TAVI, bradycardia, Cardiology and Cardiovascular Medicine, Bradycardia, medicine.medical_specialty, Cardiac resynchronization therapy, Guidelines, Physiology (medical), Internal medicine, medicine, Humans, Task force, business.industry, Stroke Volume, 1103 Clinical Sciences, medicine.disease, biology.organism_classification, Heart Rhythm, Cardiovascular System & Hematology, Heart failure, Artificial cardiac pacemaker, business, Atrioventricular block
Abstract

These are the clinical practice guidelines of the European Society of Cardiology on cardiac pacing and cardiac resynchronization therapy, from 2021.

Published
2022
Full Text
View/download PDF

24. Comprehensive assessment of myocardial remodeling in ischemic heart disease by synchrotron propagation based X-ray phase contrast imaging

Author

Planinc I, Garcia-Canadilla P, Dejea H, Ilic I, Guasch E, MATIAS ZAMORA RODRÍGUEZ, Fàtima Crispi Brillas, Stampanoni M, Milicic D, Bijnens B, Bonnin A, and Cikes M

Abstract

Cardiovascular research is in an ongoing quest for a superior imaging method to integrate gross-anatomical information with microanatomy, combined with quantifiable parameters of cardiac structure. In recent years, synchrotron radiation-based X-ray Phase Contrast Imaging (X-PCI) has been extensively used to characterize soft tissue in detail. The objective was to use X-PCI to comprehensively quantify ischemic remodeling of different myocardial structures, from cell to organ level, in a rat model of myocardial infarction. Myocardial infarction-induced remodeling was recreated in a well-established rodent model. Ex vivo rodent hearts were imaged by propagation based X-PCI using two configurations resulting in 5.8 µm and 0.65 µm effective pixel size images. The acquired datasets were used for a comprehensive assessment of macrostructural changes including the whole heart and vascular tree morphology, and quantification of left ventricular myocardial thickness, mass, volume, and organization. On the meso-scale, tissue characteristics were explored and compared with histopathological methods, while microstructural changes were quantified by segmentation of cardiomyocytes and calculation of cross-sectional areas. Propagation based X-PCI provides detailed visualization and quantification of morphological changes on whole organ, tissue, vascular as well as individual cellular level of the ex vivo heart, with a single, non-destructive 3D imaging modality.

Published
2021

25. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction

Author

Pfeffer, MA, Claggett, B, Lewis, EF, Granger, CB, Kober, L, Maggioni, AP, Mann, DL, McMurray, JJV, Rouleau, JL, Solomon, SD, Steg, PG, Berwanger, O, Cikes, M, De Pasquale, CG, East, C, Fernandez, A, Jering, K, Landmesser, U, Mehran, R, Merkely, B, Mody, FV, Petrie, MC, Petrov, I, Schou, M, Senni, M, Sim, D, van der Meer, P, Lefkowitz, M, Zhou, Y, Gong, J, Braunwald, E, Sionis A., and PARADISE-MI Invest & Comm

Abstract

Sacubitril-Valsartan in Acute Myocardial Infarction In a randomized trial, 5661 patients with acute myocardial infarction and a reduced left ventricular ejection fraction, pulmonary congestion, or both were assigned to receive either sacubitril-valsartan or ramipril. At a median of 22 months, there was no significant difference between the two groups in the incidence of death from cardiovascular causes or incident heart failure. Background In patients with symptomatic heart failure, sacubitril-valsartan has been found to reduce the risk of hospitalization and death from cardiovascular causes more effectively than an angiotensin-converting-enzyme inhibitor. Trials comparing the effects of these drugs in patients with acute myocardial infarction have been lacking. Methods We randomly assigned patients with myocardial infarction complicated by a reduced left ventricular ejection fraction, pulmonary congestion, or both to receive either sacubitril-valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily) or ramipril (5 mg twice daily) in addition to recommended therapy. The primary outcome was death from cardiovascular causes or incident heart failure (outpatient symptomatic heart failure or heart failure leading to hospitalization), whichever occurred first. Results A total of 5661 patients underwent randomization; 2830 were assigned to receive sacubitril-valsartan and 2831 to receive ramipril. Over a median of 22 months, a primary-outcome event occurred in 338 patients (11.9%) in the sacubitril-valsartan group and in 373 patients (13.2%) in the ramipril group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P=0.17). Death from cardiovascular causes or hospitalization for heart failure occurred in 308 patients (10.9%) in the sacubitril-valsartan group and in 335 patients (11.8%) in the ramipril group (hazard ratio, 0.91; 95% CI, 0.78 to 1.07); death from cardiovascular causes in 168 (5.9%) and 191 (6.7%), respectively (hazard ratio, 0.87; 95% CI, 0.71 to 1.08); and death from any cause in 213 (7.5%) and 242 (8.5%), respectively (hazard ratio, 0.88; 95% CI, 0.73 to 1.05). Treatment was discontinued because of an adverse event in 357 patients (12.6%) in the sacubitril-valsartan group and 379 patients (13.4%) in the ramipril group. Conclusions Sacubitril-valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident heart failure than ramipril among patients with acute myocardial infarction. (Funded by Novartis; PARADISE-MI ClinicalTrials.gov number, .)

Published
2021

26. Automated Pattern Recognition in Whole-Cardiac Cycle Echocardiographic Data: Capturing Functional Phenotypes with Machine Learning

Author

Loncaric F, Castellote PM, Sanchez-Martinez S, Fabijanovic D, Nunno L, Mimbrero M, Sanchis L, Doltra A, Montserrat S, Cikes M, Fàtima Crispi Brillas, Piella G, Sitges M, and Bijnens B

Subjects
Remodeling, Machine learning, Speckle-tracking, Arterial hypertension, Clustering
Abstract

BACKGROUND: Echocardiography provides complex data on cardiac function that can be integrated into patterns of dysfunction related to the severity of cardiac disease. The aim of this study was to demonstrate the feasibility of applying machine learning (ML) to automate the integration of echocardiographic data from the whole cardiac cycle and to automatically recognize patterns in velocity profiles and deformation curves, allowing the identification of functional phenotypes. METHODS: Echocardiography was performed in 189 clinically managed patients with hypertension and 97 healthy individuals without hypertension. Speckle-tracking analysis of the left ventricle and atrium was performed, and deformation curves were extracted. Aortic and mitral blood pool pulsed-wave Doppler and mitral annular tissue pulsed-wave Doppler velocity profiles were obtained. These whole-cardiac cycle deformation and velocity curves were used as ML input. Unsupervised ML was used to create a representation of patients with hypertension in a virtual space in which patients are positioned on the basis of the similarity of their integrated whole-cardiac cycle echocardiography data. Regression methods were used to explore patterns of echocardiographic traces within this virtual ML-derived space, while clustering was used to define phenogroups. RESULTS: The algorithm captured different patterns in tissue and blood-pool velocity and deformation profiles and integrated the findings, yielding phenotypes related to normal cardiac function and others to advanced remodeling associated with pressure overload in hypertension. The addition of individuals without hypertension into the ML-derived space confirmed the interpretation of normal and remodeled phenotypes. CONCLUSIONS: ML-based pattern recognition is feasible from echocardiographic data obtained during the whole cardiac cycle. Automated algorithms can consistently capture patterns in velocity and deformation data and, on the basis of these patterns, group patients into interpretable, clinically comprehensive phenogroups that describe structural and functional remodeling. Automated pattern recognition may potentially aid interpretation of imaging data and diagnostic accuracy.

Published
2021

36. EP09.93: Cardiac remodelling and exercise tolerance in small for gestational age: a follow‐up cohort study from preadolescence into adolescence.

Author

Reyes, R.H. Novoa, Fabijanovic, D., Vellve, K., Loncaric, F., Rodriguez‐Lopez, M., Sepúlveda‐Martínez, A., Sarvari, S., Valenzuela‐Alcaraz, B., Crovetto, F., Faner, R., Agusti, A., Sitges, M., Cikes, M., Bernardino, G., Blanco, I., Bijnens, B., and Crispi, F.

Subjects
SMALL for gestational age, EXPIRATORY flow, EXERCISE tolerance, PULMONARY artery, EXERCISE tests
Abstract

This article discusses a study conducted in Spain that aimed to assess the cardiovascular structure and function, as well as exercise tolerance, in adolescents born small for gestational age (SGA). The study followed a cohort of 30 SGA adolescents and 28 normal birthweight controls from preadolescence to adolescence. The results showed that while signs of cardiac remodelling and dysfunction were evident in SGA individuals during preadolescence, no significant differences in left ventricular dimensions or deformation were observed in SGA adolescents. However, SGA adolescents did have markedly reduced exercise tolerance. Further research is needed to understand the causes of these findings and their potential association with increased cardiovascular mortality among adults born SGA. [Extracted from the article]

Published
2024
Full Text
View/download PDF

43. Gender differences in acute coronary syndrome: experience from the Croatian branch of the ISACS-CT registry

Author

Loncaric, F, primary, Mjehovic, P, additional, Sabljak, D, additional, Vlahovic, V, additional, Vinkovic, I, additional, Radic, T, additional, Klaric, K, additional, Dakic, A, additional, Adamovic, I, additional, Bunic, M, additional, Pavasovic, S, additional, Jakus, N, additional, Fabijanovic, D, additional, Cikes, M, additional, and Milicic, D, additional

Published
2020
Full Text
View/download PDF

44. Impact of Progressive Aortic Regurgitation on Outcomes after Continuous Flow Left Ventricular Assist Device Implantation

Author

Gasparovic, H., primary, Jakus, N., additional, Brugts, J., additional, Rubiś, P., additional, Gaizauskas, E., additional, Van Craenenbroeck, E., additional, Pouleur, A., additional, Barge-Caballero, E., additional, Grundmann, S., additional, Gkouziouta, A., additional, D'Amario, D., additional, Flammer, A., additional, Petricevic, M., additional, Biocina, B., additional, Milicic, D., additional, Ruschitzka, F., additional, and Cikes, M., additional

Published
2020
Full Text
View/download PDF

45. ICD Therapy Confers No Survival Advantage in a Global LVAD Population: Insights from the Trans-Atlantic Registry on VAD and Transplant (TRAViATA)

Author

Braun, O., primary, Brambatti, M., additional, Shah, P., additional, Cipriani, M., additional, Veenis, J., additional, Bui, Q., additional, Hong, K., additional, de Heyning, C.Van, additional, Perna, E., additional, Timmermans, P., additional, Cikes, M., additional, Gjesdal, G., additional, Partida, C., additional, Potena, L., additional, Masetti, M., additional, Loforte, A., additional, Jakus, N., additional, Nilsson, J., additional, De Bock, D., additional, Minto, J., additional, Brugts, J., additional, Sterken, C., additional, Van den Bossche, K., additional, Rega, F., additional, Sing, R., additional, Russo, C., additional, Pretorius, V., additional, Klein, L., additional, Frigerio, M., additional, Adler, E., additional, and Ammirati, E., additional

Published
2020
Full Text
View/download PDF

46. Safety of sacubitril-valsartan vs. ramipril in left ventricular assist device carriers and comparison of NTproBNP levels - a pilot study

Author

Jakus, N, Ister, R, Planinc, I, Skoric, B, Jurin, H, Samardzic , J, Lovric, D, Ljubas Macek, J, Fabijanovic, D, Milicic, D, and Cikes, M.

Subjects
sacubitril-valsartan, left ventricular assist device
Abstract

Background: Currently, there is no consensus on the optimal medical therapy for patients after left ventricular assist device (LVAD) implantation, but usually the HFrEF therapy is continued beyond implant. We compared NT-proBNP values in LVAD patients treated with ramipril or sacubitril/valsartan (sac/val).Patient sand Methods: A single centre, retrospective study included data from 26 patients(88% male, mean age 59±11 years). 54% were continuously treated with ramipril, and 46% were switched to sac/val. The median follow-up was 13.3 months(IQR 8.5-15.4).Results:Baseline patient data are presented in Table 1. Throughout the followup, the mean arterial blood pressure, creatinine and glomerular filtration rate (GFR)values did not change significantly (Figure 1a). A decrease in NT-proBNP values was noted in both groups, although without significant difference between them. However, a difference in trends expressed as negative logarithms of ratios of NT- proBNPat 3 months follow up and at baseline is seen in the sac/val group compared to those on ramipril, achieving significance (p=0.009) for the low medication doses(Figure 1b). During follow-up, 3 patients died in the ramipril subgroup and none in the sac/val group, but the sample size precluded survival analyses.Conclusion: Our data suggest a good safety profile of sac/val in LVAD recipients. A decrease in NT-proBNP values is seen in patients in both treatment groups, with results suggestive of a decrease in the biomarker with sac/val. However, a larger prospective randomized study is required to establish the consistency of this finding and its translation to treatment benefit.

Published
2019

47. 155 Myocardial work in hypertension and mitral regurgitation- insights from non-invasive assessment of left ventricular pressure-strain relations

Author

Loncaric, F, primary, Marciniak, M, additional, Nunno, L, additional, Fernandes, J F, additional, Mimbrero, M, additional, Tirapu, L, additional, Fabijanovic, D, additional, Sanchis, L, additional, Doltra, A, additional, Cikes, M, additional, Lamata, P, additional, Bijnens, B, additional, and Sitges, M, additional

Published
2020
Full Text
View/download PDF

48. P735 Septal curvature - a novel, semi-automated parameter to aid in recognition of basal septal hypertrophy in arterial hypertension

Author

Loncaric, F, primary, Marciniak, M, additional, Fernandes, J F, additional, Gilbert, A, additional, Nunno, L, additional, Mimbrero, M, additional, Tirapu, L, additional, Sanchis, L, additional, Doltra, A, additional, Fabijanovic, D, additional, Cikes, M, additional, Lamata, P, additional, Bijnens, B, additional, and Sitges, M, additional

Published
2020
Full Text
View/download PDF

49. P3836Myocardial work distribution in hypertensive patients with basal septal hypertrophy - a non-invasive assessment with left ventricular pressure-strain relations

Author

Loncaric, F, primary, Marciniak, M, additional, Fernandes, J F, additional, Nunno, L, additional, Mimbrero, M, additional, Tirapu, L, additional, Sanchis, L, additional, Doltra, A, additional, Fabijanovic, D, additional, Cikes, M, additional, Lamata, P, additional, Bijnens, B, additional, and Sitges, M, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results